Expression of PDL-1 Receptors in Prostate Cancer Patients and its Association with Tumour Aggressiveness: A Cross-sectional Study

Prostate cancers are infiltrated with Programmed Death-1 (PD-1) expressing Cluster of Differentiation (CD)8+ T-cells which interact with Programmed Death Ligand-1 (PDL-1) receptors on Tumour Cells (TC). However, in many studies, male with prostate cancer did not respond to monotherapy (PDL blockade). This unresponsiveness could be due to the fact that prostate cancer usually does not express PD-L1. The PDL-1 expression has demonstrated a significant correlation with increased risk of disease progression in various tumours but data regarding its role in prostate cancer is conflicting. Aim: To study the occurrence rate of PDL-1 expression and itsassociation with tumour aggressiveness in prostate cancer. Materials and Methods: This cross-sectional observational study was conducted at ABVIMS and Dr. Ram Manohar Hospital, New Delhi, India, from October 1st, 2018 to April 30th, 2020. A total of 120 males with prostate cancer who had their diagnosis established by a prostate biopsy were included. Histopathology reports were analysed and PDL-1 immunohistochemical staining was carried out with PD-L1 monoclonal antibodies. PD-L1 expression on TCs was defined by the percentage of PD-L1 positive TCs ( 40), high Gleason score (≥7), distant metastasis and cases with lymphovascular invasion. Conclusion: Present study suggests that PD-L1 correlates with the tumour aggressiveness in prostate cancer patients and can be used for the identification of more aggressive diseases.